Preclinical Alzheimer's disease represents the phase where the brain undergoes changes associated with Alzheimer's, such as the formation of amyloid plaques and tau tangles, well before any symptoms are evident. During this period, individuals typically do not exhibit noticeable cognitive decline, although minor alterations in memory or thinking may occur. Identifying preclinical Alzheimer's often involves advanced biomarker tests, including PET scans and cerebrospinal fluid analysis, to detect these early pathological changes. Recognizing this stage is essential for the development of interventions aimed at delaying or preventing the onset of symptomatic Alzheimer's. Early identification enables proactive measures, such as lifestyle modifications and participation in clinical trials, offering a proactive approach to managing and potentially altering the disease's trajectory.
Jacqueline Tuppen
Cogs Club, United Kingdom
Yong Xiao Wang
Albany Medical College, United States
Kaoru Sakatani
The University of Tokyo, Japan
Suren A Tatulian
University of Central Florida, United States
Constantina Mizis
The Latino Alzheimer’s and Memory Disorders Alliance, United States
Paul Y Song
NKGen Biotech, United States
Marco Ruggiero
Silver Spring Sagl, Switzerland
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Cogs Club: Making a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States